Notice2022-11252

Bulk Manufacturer of Controlled Substances Application: Invizyne Technologies, Inc.

Primary source

Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.

Published
May 25, 2022

Issuing agencies

Justice DepartmentDrug Enforcement Administration

Abstract

Invizyne Technologies, Inc. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.

Full Text

<html>
<head>
<title>Federal Register, Volume 87 Issue 101 (Wednesday, May 25, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 101 (Wednesday, May 25, 2022)]
[Notices]
[Page 31911]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-11252]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-1002]


Bulk Manufacturer of Controlled Substances Application: Invizyne 
Technologies, Inc.

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

-----------------------------------------------------------------------

SUMMARY: Invizyne Technologies, Inc. has applied to be registered as a 
bulk manufacturer of basic class(es) of controlled substance(s). Refer 
to SUPPLEMENTARY INFORMATION listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), 
and applicants therefore, may submit electronic comments on or 
objections to the issuance of the proposed registration on or before 
July 25, 2022. Such persons may also file a written request for a 
hearing on the application on or before July 25, 2022.

ADDRESSES: The Drug Enforcement Administration requires that all 
comments be submitted electronically through the Federal eRulemaking 
Portal, which provides the ability to type short comments directly into 
the comment field on the web page or attach a file for lengthier 
comments. Please go to <a href="https://www.regulations.gov">https://www.regulations.gov</a> and follow the 
online instructions at that site for submitting comments. Upon 
submission of your comment, you will receive a Comment Tracking Number. 
Please be aware that submitted comments are not instantaneously 
available for public view on <a href="https://www.regulations.gov">https://www.regulations.gov</a>. If you have 
received a Comment Tracking Number, your comment has been successfully 
submitted and there is no need to resubmit the same comment.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this 
is notice that on March 14, 2022, Invizyne Technologies, Inc., 750 
Royal Oaks Drive, Suite 106, Monrovia, California 91016-6357, applied 
to be registered as a bulk manufacturer of the following basic 
class(es) of controlled substance(s):

------------------------------------------------------------------------
                                           Drug
          Controlled substance             code          Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols...................    7370  I
------------------------------------------------------------------------

    The company plans to bulk manufacture the listed controlled 
substance for the internal use intermediates or for sale to its 
customers. In reference to drug code 7370 (Tetrahydrocannabinols), the 
company plans to bulk manufacture this drug as synthetic. No other 
activities for this drug code is authorized for this registration.

Kristi N. O'Malley,
Assistant Administrator.
[FR Doc. 2022-11252 Filed 5-24-22; 8:45 am]
BILLING CODE P


</pre></body>
</html>
Indexed from Federal Register on May 25, 2022.

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.